EcoDrugPlus

Androgen Receptor

Ensembl ID : ENSMMNG00015009371
Gene Symbol: AR
1 Cross references
277 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSMMNG00015019672
Gene Symbol: ACE
3 Cross references
93 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSMMNG00015004396
Gene Symbol: AGTR1
1 Cross references
207 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSMMNG00015015711
Gene Symbol: AGTR2
3 Cross references
191 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSMMNG00015021976
Gene Symbol: APLNR
3 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSMMNG00015000151
Gene Symbol: APH1A
1 Cross references
136 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSMMNG00015010212
Gene Symbol: APH1B
3 Cross references
190 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSMMNG00015009765
Gene Symbol: APEX1
3 Cross references
212 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSMMNG00015019970
Gene Symbol: ALOX12
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSMMNG00015011015
Gene Symbol: ALOX5
3 Cross references
219 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSMMNG00015020175
Gene Symbol: ALOX5AP
3 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSMMNG00015018836
Gene Symbol: AVPR1A
1 Cross references
264 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).